Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
La salud financiera de Vertex Minerals se determina situando a la compañía en un ranking según más de 100 factores frente a las empresas del sector Materiales y que operan en los mercados ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback